NDAINJECTIONINJECTABLE
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
DOCETAXEL (docetaxel) by Medica Corp is functions. Approved for breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma. First approved in 2015.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Docetaxel is a taxane chemotherapy agent that stabilizes microtubules and inhibits mitosis, approved for treatment across 12 solid tumor indications including breast, lung, prostate, and ovarian cancers. It is administered intravenously and represents a foundational cytotoxic agent in oncology regimens. The drug binds to tubulin and promotes microtubule assembly while preventing disassembly, leading to cell cycle arrest and apoptosis.
$43KPart D
Peak7.4 years to LOEProduct is at peak maturity with minimal Medicare Part D utilization; team focus is on maintaining market position rather than expansion, suggesting stable but modest headcount.
Mechanism of Action
functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the…
Indications (3)
Worked on DOCETAXEL at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.